Michael Childs, MD
Urology · Little Rock, ARNPI 1568669448
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,114 of the $8,054 with a category attached, or 88.3%. It is spread thinly across 41 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,925, 2.5 times the $761 reported in 2019.
Across 289 payments — averaging $27.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Teleflex LLC$1K
- Johnson & Johnson$724
- Axonics, Inc.$654
- Dendreon Pharmaceuticals LLC$649
- Astellas Pharma US Inc$467
- plus $3K from 35 others
What the payments were for
- Travel & lodging$6879%
- Food & beverage$7,11488%
- Education$2533%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$622
- Bulkamid$460
- PROVENGE$264
- UroLift$264
- GENERAL ERECTILE DYSFUNCTION$234
- Barrigel$149
- UroLift System$135
- Erleada$125
- AquaBeam Robotic System$112
- SPACEOAR VUE$101
How this compares
$8,054 in reported general payments places this provider in the 60th percentile of 88 urology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 30 | $431,784 |
| XtandiEnzalutamide | 25 | $352,416 |
| GemtesaVibegron | 151 | $86,815 |
| Abiraterone Acetate | 22 | $61,281 |
| MyrbetriqMirabegron | 38 | $25,071 |
| Tamsulosin Hcl | 361 | $5,630 |
| Estradiol | 36 | $2,254 |
| Cephalexin | 116 | $1,200 |
| Silodosin | 18 | $1,041 |
| Finasteride | 65 | $818 |
| Oxybutynin Chloride ErOxybutynin Chloride | 38 | $807 |
| Testosterone Cypionate | 37 | $794 |
| Dutasteride | 18 | $625 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 16 | $601 |
| Pentoxifylline | 14 | $521 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $724 | $431,78430 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $467 | $377,48663 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $241 | $86,815151 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 88 urology providers in Arkansas.
Other urology in Little Rock
- Donald MooneyLittle Rock$148K
- Timothy GoodsonLittle Rock$147K
- Caleb BozemanLittle Rock$136K
- David CoussensLittle Rock$134K
- Timothy LangfordLittle Rock$133K
- Kevin ClaybrookLittle Rock$132K
- Gail JonesLittle Rock$128K
- John MooreLittle Rock$19K
- Bruno Lopes Cancado MachadoLittle Rock$7K
- Marcelo BigarellaLittle Rock$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.